# Aktis Oncology, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Aktis Oncology, Inc.). ## Overview Aktis Oncology, Inc. is a U.S.-based clinical-stage biopharmaceutical company developing targeted radiopharmaceutical therapies for solid tumors. Its platform centers on miniprotein radioconjugates designed to deliver alpha-emitting radioisotopes to specific cancer targets, with programs aimed at multiple tumor types. ## Products & services • [225Ac]Ac-AKY-1189 for Nectin-4 expressing tumors • [225Ac]Ac-AKY-2519 for B7-H3 expressing tumors • Miniprotein radioconjugate platform • Discovery and preclinical oncology programs • Clinical development and translational research services • Collaboration-based radiopharmaceutical development - **Lead radiopharmaceutical candidate** (0%) — Clinical-stage alpha-emitting radioconjugate programs designed for specific tumor targets. - **Preclinical pipeline** (0%) — Discovery and IND-enabling programs for additional targeted oncology candidates. - **Platform technology** (0%) — Miniprotein radioconjugate platform used to identify and advance new tumor targets. - **Collaboration revenue** (100%) — Revenue recognized from research collaboration agreements with strategic partners. - [225Ac]Ac-AKY-1189 for Nectin-4 expressing tumors - [225Ac]Ac-AKY-2519 for B7-H3 expressing tumors - Miniprotein radioconjugate platform - Discovery and preclinical oncology programs - Clinical development and translational research services - Collaboration-based radiopharmaceutical development ## Customers Aktis Oncology’s direct customers are primarily collaboration partners and, eventually, oncology physicians and cancer centers that would use approved radiopharmaceuticals. In the current stage, value is created through licensing, research collaboration, and development partnerships rather than commercial product sales. If approved, the end users would be patients with solid tumors expressing the relevant targets, treated through specialized oncology and nuclear medicine channels. - **Strategic collaboration partners** (primary) — Biopharma partners that fund or co-develop radiopharmaceutical programs and share development risk. - **Oncology treatment centers** (secondary) — Specialty cancer centers that would administer approved radiopharmaceutical therapies. - **Patients with target-expressing solid tumors** (primary) — Patients whose tumors express Nectin-4, B7-H3, or other selected targets. - **Nuclear medicine and radiopharmacy networks** (secondary) — Specialized sites that would handle isotope preparation, handling, and administration. - Pharmaceutical collaborators funding or co-developing programs - Oncology physicians treating target-positive solid tumors - Cancer centers and hospital systems with radiopharmaceutical capability - Patients with Nectin-4 or B7-H3 expressing tumors - Potential licensees seeking access to the platform and IP ## Geography Aktis Oncology is headquartered in the United States and conducts its research, development, and corporate activities from there. Its business model is global in potential reach because radiopharmaceutical candidates may be developed for broad oncology use, but the disclosed operating footprint is centered in the U.S. The company also depends on external vendors and supply sources that may be located outside the U.S. for isotopes, manufacturing, and research services. - Headquartered and operated from the United States - Clinical development and corporate functions are U.S.-based - Future commercialization could extend to multiple markets - Supply chain depends on external vendors and isotope sources - No country-level revenue disclosure beyond collaboration revenue ## Strategy The company is focused on broadening targeted radiopharmaceuticals beyond the best-known tumor targets by advancing next-generation candidates against new antigens. It is also building supply, manufacturing, and development capabilities so that clinical demand and eventual commercial demand can be supported across multiple indications. Collaboration, licensing, and capital raising remain important to fund development until product sales are possible. - **Advance lead and follow-on radiopharmaceutical candidates** (short-term) — Clinical progress is required to validate the platform and create future product value. - **Build manufacturing and isotope supply capabilities** (medium-term) — Reliable access to 225Ac and production capacity is essential for trials and eventual commercialization. - **Expand partnerships and non-dilutive funding sources** (short-term) — Development-stage oncology programs require substantial capital before product revenue exists. - Advance [225Ac]Ac-AKY-1189 through clinical development - Move [225Ac]Ac-AKY-2519 through IND-enabling studies - Expand the miniprotein radioconjugate platform - Secure isotope supply and manufacturing capacity - Use collaborations and licensing to fund development ## Risks Aktis Oncology faces the typical risks of a clinical-stage biotech company: uncertain trial outcomes, regulatory delays, and the possibility that candidates never reach approval. Its radiopharmaceutical model also depends on specialized isotope supply, manufacturing execution, and intellectual property protection, all of which can constrain development or commercialization. Because the company has no approved products, it remains exposed to financing risk and to competition from other oncology and radiopharmaceutical platforms. - **Clinical development failure** [critical] — The company has no approved products and depends on successful trial outcomes to create value. - **Radioisotope supply constraints** [high] — The business requires sufficient 225Ac and related isotopes to run trials and support future supply. - **Manufacturing and scale-up execution** [high] — Radiopharmaceuticals require specialized handling, production, and logistics capabilities. - **Financing and dilution risk** [high] — Development-stage operations require ongoing capital before product sales begin. - **Competitive pressure** [medium] — Other companies are developing targeted radiopharmaceuticals and oncology therapies for similar markets. - Clinical trials may fail or produce insufficient efficacy or safety data - Regulatory review could delay or block product approval - 225Ac and other isotope supply may be limited or disrupted - Manufacturing scale-up may be difficult for radiopharmaceuticals - Competition from other oncology and radiopharma platforms is intense - Future funding needs may force dilution or slower development ## Accounting The main accounting issue is collaboration revenue recognized over time using a cost-incurred input method, which can create quarter-to-quarter variability as development activity changes. As a clinical-stage company, most spending is expensed as research and development, while milestone, sublicense, and royalty obligations under licensing agreements remain contingent and judgmental. Investors should also watch stock-based compensation, capitalized or expensed facility and manufacturing costs, and estimates tied to public-company operating expenses and tax attributes. - **Collaboration revenue recognition** — Can create uneven quarterly revenue recognition - **Research and development expense timing** — Affects operating loss comparability across periods - **Contingent milestone and royalty obligations** — Potential future cash outflows and expense recognition - **Stock-based compensation** — Impacts reported R&D and G&A expense - **NOLs and tax credits** — Limits near-term tax benefit recognition - Collaboration revenue is recognized over time using cost incurred - R&D expense timing drives large quarterly swings in reported results - Milestone and royalty obligations are contingent and judgmental - Stock-based compensation is a major operating expense component - Tax loss carryforwards and credits may not be realizable --- *Last updated: 2026-08-11T04:46:19.810886+00:00*